CD40LG and infection: Subsequently, other cohort studies performed in the Brazilian Amazon regarding on the dynamics of the clinical–immunological profiles of infection concluded that 1–3% of III profile cases can progress to AVL, which was confirmed in two situations when it was performed the preclinical diagnosis of AVL by demonstrating IgM-antibody response in two III asymptomatic individuals, six weeks before both individuals manifested the first signs and/or symptoms of AVL [21,22].